Roivant Sciences Ltd. ROIV
At closeNov 4, 2026, 5:04 PM EST
After hours · Nov 4, 5:04 PM ET
- YTD
- +76.18%
- 1 year
- +92.40%
- Market cap
- 27.61B
- Revenue (ttm)
- 7.53M
- EPS (ttm)
- -0.53
- Shares out
- 722.32M
- Forward P/E
- -27.47
- YTD return
- +76.18%
- 1-year return
- +92.40%
- Volume
- 11.67M
- Avg volume
- 7.64M
- Open
- 36.62
- Previous close
- 36.04
- Day's range
- 35.71 – 38.52
- 52-week range
- 19.62 – 42.50
- Beta
- 1.20
- Analysts
- Strong Buy
- Price target
- 50.00 (+30.8%)
- Earnings date
- Nov 9, 2026
YTD +16.30 (+74.33%)
Key statistics
- Enterprise value
- 22.99B
- PEG ratio
- 0.00
- Price / sales
- 3666.28
- Price / book
- 6.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -33.50%
- Free cash flow
- -1.12B
- Total cash
- 3.84B
- Total debt
- 107.15M
- Return on equity
- -8.52%
- Short % of float
- 7.56%
- 50-day average
- 36.63
- 200-day average
- 31.63
Analyst view
Consensus: strong buy
- Target (low)
- 41.00
- Target (mean)
- 50.00
- Target (high)
- 62.00
- Strong buy2
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.44866.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.36664 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.29962 | -0.33 | -0.03 | -10.14% |
| May 20, 2026 | Mar 31, 2026 | -0.28931 | -0.2792 | +0.01 | +3.49% |
| Feb 6, 2026 | Dec 31, 2025 | -0.29954 | -0.24 | +0.06 | +19.88% |
| Nov 10, 2025 | Sep 30, 2025 | -0.3198 | -0.20193 | +0.12 | +36.86% |
| Aug 11, 2025 | Jun 30, 2025 | -0.2497 | -0.25175 | 0.00 | -0.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Citigroup | main | Buy | Buy |
| Oct 12, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 17, 2026 | Stifel | init | — | Buy |
| Sep 9, 2026 | TD Cowen | main | Buy | Buy |
| Sep 9, 2026 | Guggenheim | main | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- roivant.com
News
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56 
If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today 
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript 
Why Is Roivant Sciences Stock Surging Wednesday? 
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) 
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 
Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A. 
Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Your note
Sign in to keep a note on ROIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GLINE MATTHEW | Chief Executive Officer | Sale | Apr 15, 2026 | 16,736,100 |
| GOLD DANIEL ALLEN | Director | Sale | Jun 29, 2026 | 0 |
| KUMAR RAKHI | Officer | Sale | Feb 12, 2025 | 163,264 |
| MANCHESTER KEITH S | Director | Stock Award(Grant) | Sep 15, 2026 | 1,753,460 |
| OREN ILAN | Director | Stock Award(Grant) | Oct 22, 2026 | 124,490 |
| PULIK RICHARD | Chief Financial Officer | Stock Award(Grant) | Apr 19, 2026 | 297,511 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.22% | 81,020,390 | 3.10B | Jun 29, 2026 |
| Blackrock Inc. | 6.68% | 48,236,091 | 1.84B | Jun 29, 2026 |
| Morgan Stanley | 5.90% | 42,592,905 | 1.63B | Jun 29, 2026 |
| QVT Financial LP | 3.28% | 23,723,074 | 906.93M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.06% | 22,123,198 | 845.77M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.00% | 21,641,339 | 827.35M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.19% | 23,009,528 | 879.65M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.67% | 19,297,013 | 737.72M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.21% | 15,987,737 | 611.21M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.60% | 11,546,280 | 441.41M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 0.96% | 6,900,746 | 263.82M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.92% | 6,658,616 | 254.56M | Jun 29, 2026 |